Molecular Templates to Screen Targets for ImClone | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Templates, a Georgetown, Texas-based firm that has developed a targeted biologics platform, said that it has signed an agreement to screen potential drug targets for ImClone Systems, a wholly-owned subsidiary of Eli Lilly.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.